Sign inJoin Free
DashboardSign out
Regulatory Coordinator
Full course · Protocol Amendment Management
Regulatory Coordinator
Full course · Protocol Amendment Management
Free Lesson Preview
Module 1: Lesson 1

Teaches RCs to manage the operationally complex window between IRB approval of an amended consent form and completion of reconsent for all affected participants, including visit conduct decision trees, scenario-based response protocols, and documentation requirements.
The IRB approved Amendment 3 on Monday morning. By Monday afternoon, the coordinator had updated the regulatory binder, filed the approval letter, and begun building the reconsent schedule using the tracking system from the previous lesson. Forty-eight participants need reconsent. The team estimated two weeks to reach everyone -- a reasonable timeline, given the visit schedule and the site's capacity for reconsent conversations.
It is now Wednesday. A participant has arrived for a scheduled visit. This visit includes standard labs, a joint assessment, and -- per the amendment just approved 48 hours ago -- a new biomarker blood draw that was not part of the original protocol. The participant has not been reconsented. The new consent form is printed and ready, but the participant walked through the door expecting a routine visit, not a consent conversation about changes to the study.
What happens now?
This is the gap period: the window between the moment an amended consent form receives IRB approval and the moment every affected participant has been reconsented. It is, in my experience, the most operationally treacherous phase of any amendment cycle. Not because the regulatory requirements are ambiguous -- they are actually quite clear -- but because the gap period is where regulatory obligations collide with clinical reality. Participants do not pause their disease progression while the site completes administrative processes. They arrive when their visit schedule says to arrive. They experience adverse events on their own timeline. They call the site with questions that now have different answers than they did last week.
The previous lessons in this module built the infrastructure: determining when reconsent is required, designing the reconsent plan, and deploying the tracking system that monitors completion. This lesson addresses what the RC must build to manage the interval before that tracking system shows 100% -- the procedures, decision frameworks, and documentation standards that govern site operations during the gap.
By the end of this lesson, you will be able to:
Continue with the Regulatory Coordinator track
Enroll to access all courses in the Regulatory Coordinator track.
Unlock the full courseFree Lesson Preview
Module 1: Lesson 1

Teaches RCs to manage the operationally complex window between IRB approval of an amended consent form and completion of reconsent for all affected participants, including visit conduct decision trees, scenario-based response protocols, and documentation requirements.
The IRB approved Amendment 3 on Monday morning. By Monday afternoon, the coordinator had updated the regulatory binder, filed the approval letter, and begun building the reconsent schedule using the tracking system from the previous lesson. Forty-eight participants need reconsent. The team estimated two weeks to reach everyone -- a reasonable timeline, given the visit schedule and the site's capacity for reconsent conversations.
It is now Wednesday. A participant has arrived for a scheduled visit. This visit includes standard labs, a joint assessment, and -- per the amendment just approved 48 hours ago -- a new biomarker blood draw that was not part of the original protocol. The participant has not been reconsented. The new consent form is printed and ready, but the participant walked through the door expecting a routine visit, not a consent conversation about changes to the study.
What happens now?
This is the gap period: the window between the moment an amended consent form receives IRB approval and the moment every affected participant has been reconsented. It is, in my experience, the most operationally treacherous phase of any amendment cycle. Not because the regulatory requirements are ambiguous -- they are actually quite clear -- but because the gap period is where regulatory obligations collide with clinical reality. Participants do not pause their disease progression while the site completes administrative processes. They arrive when their visit schedule says to arrive. They experience adverse events on their own timeline. They call the site with questions that now have different answers than they did last week.
The previous lessons in this module built the infrastructure: determining when reconsent is required, designing the reconsent plan, and deploying the tracking system that monitors completion. This lesson addresses what the RC must build to manage the interval before that tracking system shows 100% -- the procedures, decision frameworks, and documentation standards that govern site operations during the gap.
By the end of this lesson, you will be able to:
Continue with the Regulatory Coordinator track
Enroll to access all courses in the Regulatory Coordinator track.
Unlock the full course